Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialLancet Oncol 2022 Jun 07;[EPub Ahead of Print], RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, C Suárez, A Hamzaj, C Porta, CM Hocking, ER Kessler, H Gurney, Y Tomita, J Bedke, J Zhang, B Simsek, C Scheffold, AB Apolo, TK Choueiri
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.